|
|
Article: Valeant Pharmaceuticals Acquires Rights to Nabilone in United Kingdom and Europe.
- Article from:
- Business Wire
- Article date:
- February 15, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Acquisition Expands Company's Cesamet Business in Key Markets -
ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has acquired the commercial rights to nabilone in the United Kingdom and other European markets from Cambridge Laboratories for $14 million. Valeant markets nabilone in the United States and Canada under the brand name Cesamet[R]. Nabilone is indicated for use in the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional anti-emetic treatments.
"There remains a need for cannabinoids like Cesamet for patients who ...